Sitemap
Carrie Mantha

Carrie Mantha

Investor, entrepreneur, doctor, data snob, and lover of fashion, friends, skiing, spinning, champagne, chocolate, economic policy, and good deeds.

Bio-hazard

the problem with tech hubris, press hype, & industry connivance

4 min readFeb 19, 2014

Last night I had the most wonderful dinner with a handful of investors and entrepreneurs, discussing everything from currencies to cultures and social pets to ubiquitous hackathon attendees. It was one of the most fun and stimulating conversations I've had in a long time (thank you to FF Ventures for hosting!).

One topic got under my skin a bit: the potential for open source information to contribute to medical breakthroughs. It’s not the topic that bothered me so much as its poster child: teenager Jack Andraka, who won the 2012 Intel Science Fair for his work on a test for early detection of pancreatic cancer. Google his name and you’ll see his Ted talks, his 60 minute special, and headlines like “Did This 15-Year-Old Kid Just Change the Course of Medicine?”

The reason this got under my skin is that Jack Andraka did not change the course of medicine, and we’re doing him and all of scientific innovation a grave disservice by pretending he did. Let me explain:

In 2011, then 15 year old Jack Andraka read a scientific publication suggesting that a protein called mesothelin might be a more sensitive biomarker for pancreatic cancer than what we use today. He had the idea to create a mesothelin-based pancreatic cancer test by coating the protein onto carbon nanotubule paper, which is slightly faster than traditional ELISA-based protein detection.

Impressive reasoning for a 15 year old (!), and it earned him some lab space to run a few tests in mouse models showing that the coated paper did indeed light up when exposed to pancreatic tumors in mice. Jack may have stretched a bit in his conclusion that this test was “ 28 times faster and 26,000 times less expensive” than ELISA, but his experiments won him the 2012 Intel science fair prize and a nice chunk of cash (all of which I think were totally warranted).

Get Carrie Mantha’s stories in your inbox

Join Medium for free to get updates from this writer.

Here’s where things derailed: the scientific community decided to ride the press wave and allow Jack to be made into a folk hero for open access to scientific papers (a big issue with scientists) and for pancreatic cancer research (which gets very little attention).

This funding-hungry community has a vested interest in a press-friendly “prodigy,” so no one mentioned to the media the fundamental problem with his research: medicine doesn't forego the available mesothelin ELISA tests because they’re slow or expensive (they’re not), we forego them because we know that mesothelin is a terrible biomarker for pancreatic cancer. It doesn't matter how sensitive, fast, or cheap a mesothelin test is — the protein exists in healthy people and is not specific enough to be used as a screening test. If you used a test like this to screen, you’d see far too many false positives and end up operating on healthy pancreases, likely harming far more people than you helped.

There appear to have been no attempts to commercialize this test in the 2 years since Jack won the Intel prize, and for good reason. It’s concerning, though, that none of his data has been published in a peer-reviewed journal during those two years. Despite this, the scientific community has allowed the press to run with conclusion that this young man did something hundreds of scientists and millions of dollars in research couldn't do.

I have two big problems here:

  1. This very bright teenager isn't being taught about the holes in his thinking so he can hone and direct his considerable talents toward developing something meaningful. Instead, he’s being treated as though he’s perfect and sent on a world speaking tour (quite literally!) as a guru on medical innovation. The scientific community owes Jack the decency of critiquing his work and explaining his false assumptions and logical errors, not just using him to gain attention and funding.
  2. This perpetuates the dangerous misconception that medical breakthroughs happen quickly and without a healthy respect for the challenges inherent in solving them.

“Outsiders” employing open source information, “big data” analytics, and other innovative approaches to solving important medical problems MUST be encouraged and welcomed by the scientific community. However, they must also work with that community to understand the context in which they’re operating, lest we waste their enormous potential. It’s the scientific community’s responsibility to engage and direct newcomers, not just pat them on their heads dismissively and exploit the media attention they bring (it would be nice if media outlets did a little more digging and a little less hyping as well!).

This holds true for a lot of other industries: open source information, big data, and technology in general have the potential to transform everything from agriculture to airlines and finance to fashion. These powerful tools should be handled with care, though, not wielded like a sledgehammer with no regard to the years of wisdom and end-user understanding that exist within every industry.

It is the admittedly difficult task of “disruptors” to figure out which industry beliefs to respect and which to reject as baseless dogma, but that’s exactly the kind of fine calibration the scientific community should be leading, not exploiting.

--

--

Carrie Mantha
Carrie Mantha

Written by Carrie Mantha

Investor, entrepreneur, doctor, data snob, and lover of fashion, friends, skiing, spinning, champagne, chocolate, economic policy, and good deeds.